CorMedix (CRMD) Free Cash Flow (2010 - 2025)
CorMedix (CRMD) posted Free Cash Flow of $92.7 million for Q4 2025, up 205.56% sequentially from $30.4 million in Q3 2025, and up 1748.72% YoY from $5.0 million in Q4 2024.
CorMedix (CRMD) Free Cash Flow (2010 - 2025) Analysis & Trends
CorMedix has reported Free Cash Flow for 15 years, with the latest figure at $92.7 million in Q4 2025.
- Quarterly Free Cash Flow rose 1748.72% year-over-year to $92.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $172.8 million (up 440.59% YoY) and the FY2025 annual result came in at $172.8 million, up 440.59% from the prior year.
- Free Cash Flow rose to $92.7 million in Q4 2025 per CRMD's latest filing, from $30.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $92.7 million in Q4 2025 and troughed at -$17.4 million in Q1 2024.
- A 5-year average of $1.8 million and a median of -$6.4 million in 2021 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2021 and 2025: Free Cash Flow plunged 308.37% in 2021, then soared 1748.72% in 2025.
- Over 5 years, Free Cash Flow stood at -$6.5 million in 2021, then climbed by 3.3% to -$6.3 million in 2022, then sank by 75.72% to -$11.0 million in 2023, then soared by 49.06% to -$5.6 million in 2024, then jumped by 1748.72% to $92.7 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered $92.7 million, $30.4 million, and $30.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 92.74 Mn |
| Dec 31, 2025 | 92.74 Mn |
| Sep 30, 2025 | 30.35 Mn |
| Sep 30, 2025 | 30.35 Mn |
| Jun 30, 2025 | 29.97 Mn |
| Jun 30, 2025 | 29.97 Mn |
| Mar 31, 2025 | 19.73 Mn |
| Mar 31, 2025 | 19.73 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Sep 30, 2024 | -13.66 Mn |
| Sep 30, 2024 | -13.66 Mn |
| Jun 30, 2024 | -14.07 Mn |
| Jun 30, 2024 | -14.07 Mn |
| Mar 31, 2024 | -17.37 Mn |
| Mar 31, 2024 | -17.37 Mn |
| Dec 31, 2023 | -11.04 Mn |
| Dec 31, 2023 | -11.04 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Sep 30, 2023 | -8.71 Mn |